Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

S
Shadia Jalal, MD

Primary Investigator

Overview

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.

Description

The purpose of this study is to centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies, and to obtain clinically annotated tumor tissue and patient-matched non-malignant deoxyribonucleic acid (DNA) from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the National Cancer Institute (NCI) Center for Cancer Genomics (CCG).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    lung carcinoma
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
  • Clinical stage IB (>= 4 cm), II or IIIA non-squamous non-small cell lung cancer (NSCLC)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
For a full list of participation criteria, please visit ClinicalTrials.gov.
Additional Information:
Participants will not be paid for their participation.

Updated on 16 Jan 2024. Study ID: 1502674227 (A151216)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center